Botulinum toxin injection for chronic pelvic pain: A systematic review

Fang Yuan Luo, Maryam Nasr-Esfahani, John Jarrell, Magali Robert, Fang Yuan Luo, Maryam Nasr-Esfahani, John Jarrell, Magali Robert

Abstract

Introduction: Botulinum toxin has proven therapeutic effects in alleviating pain in several myofascial disorders, with an expanding potential in chronic pelvic pain. The objective of this systematic review is to evaluate the efficacy and safety of botulinum toxin injection as an off-label treatment for female chronic pelvic pain.

Material and methods: Using PRISMA guidelines, MEDLINE, EBM Reviews, PubMed, CINAHL, TRIP Database, EMBASE, Web of Science and gray literature were searched. Studies assessing the efficacy of botulinum toxin for chronic pelvic pain in adult females, with 10 or more women, published in English up to 13 January 2020, were included. All eligible studies were reviewed and data were extracted by two independent reviewers using a standardized form. Quality of evidence was graded using the Cochrane Risk of Bias 2 tool for randomized controlled trials and the Ottawa-Newcastle scale for observational studies.

Results: In all, 491 records were screened. Seventeen articles were included in the final review: 5 randomized controlled trials and 12 observational studies. The quality of evidence ranged from low to high. There was a large degree of heterogeneity in study designs, and thus a meta-analysis was not feasible. All observational studies concluded that botulinum toxin was an effective treatment for chronic pelvic pain, with the greatest change in visual analog scale from 8.69 at baseline to 3.07 at 24 months post-injection. However, only one of the five randomized controlled trials found statistical significant differences favoring botulinum toxin in the reporting of the EQ-5D (botulinum 0.78 [0.69-1.00], control 0.69 [0.25-0.81], P = .03) and frequency of intercourse (botulinum 1 [1-1.75], placebo 1 [0-1], P = .025). The most common adverse effect was transient localized pain at injection site (6%-88%). No serious adverse events were reported.

Conclusions: Although observational studies were encouraging, there is insufficient high quality evidence to recommend botulinum toxin injection for chronic pelvic pain. However, it appears to be safe to use. Future studies of higher quality in its treatment efficacy are indicated.

Keywords: botulinum toxin; chronic pelvic pain; dyspareunia; myofascial pain; vulvodynia.

© 2020 Nordic Federation of Societies of Obstetrics and Gynecology (NFOG). Published by John Wiley & Sons Ltd.

References

REFERENCES

    1. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain. 1994;59:65-69.
    1. Oh HM, Chung ME. Botulinum toxin for neuropathic pain: a review of the literature. Toxins (Basel). 2015;7:3127-3154.
    1. Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol. 1996;87:321-327.
    1. Muhammad YY, Nossier SA, El-Dawaiaty AA. Prevalence and characteristics of chronic pelvic pain among women in Alexandria. Egypt. J Egypt Public Health Assoc. 2011;86:33-38.
    1. Jarrell JF, Vilos GA, Allaire C, et al. 164-Consensus Guidelines for the Management of Chronic Pelvic Pain. J Obstet Gynaecol Can. 2018;40:e747-e787.
    1. Brin MF, Vapnek JM. Treatment of vaginismus with botulinum toxin injections. Lancet. 1997;349:252-253.
    1. Gajraj NM. Botulinum toxin A injection of the obturator internus muscle for chronic perineal pain. J Pain. 2005;6:333-337.
    1. Thomson AJM, Jarvis SK, Lenart M, Abbott JA, Vancaillie TG. The use of botulinum toxin type A (BOTOX) as treatment for intractable chronic pelvic pain associated with spasm of the levator ani muscles. BJOG. 2005;112:247-249.
    1. Moore SJ, Kennedy SH. The Initial Management of Chronic Plevic Pain. Green-top Guideline No. 41. London: Royal College of Obstetricians & Gynaecologists; 2012.
    1. Engeler D, Baranowski AP, Borvicka J, et al. EAU Guidelines on Chronic Pelvic Pain. In: EAU Guidelines. Arnhem: EAU Guidelines Office; 2018:1-82. . Accessed May 2, 2019.
    1. Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol. 2006;108:915-923.
    1. Karp BI, Tandon H, Vigil D, Stratton P. Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders. Int Urogynecol J. 2019;30:1071-1081.
    1. Wells C, Farrah K. Injectable Botulinum Toxin for Pelvic Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2019.
    1. Dworkin RH, Turk DC, McDermott MP, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain. 2009;146:238-244.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS. 2009;6:1-6.
    1. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
    1. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ontario: Ottawa Hospital Research Institute; 2013.
    1. Pacik PT. OnabotulinumtoxinA as part of a multimodal program to treat vaginismus. J Appl Biobehav Res. 2015;20:25-36.
    1. Pacik PT, Geletta S. Vaginismus treatment: clinical trials follow up 241 patients. Sex Med. 2017;5:e114-e123.
    1. Bartley J, Nguyen L, Hasenau D, et al. Onobotuliumtoxin A versus kenalog for intravaginal trigger point injections in the treatment of chronic pelvic pain. J Urol. 2019;201:467-468.
    1. . Identifier: NCT02369068, Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain. 2015. Available online at: (Accessed 10 March 2019).
    1. . Identifier: NCT01859507, Injection of Botox in the Perineal Muscles in Resistant Cases of Vaginal Spasm (VginsmsBOTOX). Available online at: (Accessed 10 March 2019).
    1. . Identifier: NCT01967524, Multicenter Randomized Double-blind Study Evaluating the Effects of Botulinum Toxin A Associated with Ropivacaïne versus Ropivacaïne Alone in the Treatment of the Myofascial Pelviperineal Pain (MYOTOX). Available online at: (Accessed 10 March 2019).
    1. . Identifier: NCT01323829, EMG Guided Botulinum Toxin Type A Injections for Refractory High Tone Pelvic Floor Dysfunction (BTXA EMG). Available online at: (Accessed 10 March 2019).
    1. . Identifier: NCT00638066, Botulinum Toxin Injection for Treatment of Vaginismus. Available online at: (Accessed 10 March 2019).
    1. . Identifier: NCT00119886, Botox on Vulvar Vestibulitis. Available online at: (Accessed 10 March 2019).
    1. Dessie SG, Von Bargen E, Hacker MR, Haviland MJ, Elkadry E. A randomized, double-blind, placebo-controlled trial of onabotulinumtoxin A trigger point injections for myofascial pelvic pain. Am J Obstet Gynecol. 2019;221:517.e1-517.e9.
    1. Yaraghi M, Ghazizadeh S, Mohammadi F, Ashtiani EM, Bakhtiyari M. Comparing the effectiveness of functional electrical stimulation via sexual cognitive/behavioral therapy of pelvic floor muscles versus local injection of botulinum toxin on the sexual functioning of patients with primary vaginismus: a randomized clinical trial. Int Urogynecol J. 2019;30:1821-1828.
    1. Ghazizadeh S, Abedi J, Pourmatroud E, Lesanpezeshki M. Comparison of 500 units vs 250 units of botulinum toxin ( Abobotulinumtoxina ) for the treatment of severe vaginismus. J Bacteriol Mycol. 2016;3:3-6.
    1. Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol. 2004;104:922-925.
    1. Morrissey D, El-Khawand D, Ginzburg N, Wehbe S, O’Hare P, Whitmore K. Botulinum toxin A injections into pelvic floor muscles under electromyographic guidance for women with refractory high-tone pelvic floor dysfunction: A 6-month prospective pilot study. Female Pelvic Med Reconstr Surg. 2015;21:277-282.
    1. Adelowo A, Hacker MR, Shapiro A, Modest AM, Elkadry E. Botulinum toxin type A (BOTOX ) for refractory myofascial pelvic pain. Female Pelvic Med Reconstr Surg. 2013;19:288-292.
    1. Halder GE, Scott L, Wyman A, et al. Botox combined with myofascial release physical therapy as a treatment for myofascial pelvic pain. Investig Clin Urol. 2017;58:134-139.
    1. Nesbitt-Hawes EM, Won H, Jarvis SK, Lyons SD. Improvement in pelvic pain with botulinum toxin type A--Single vs. repeat injections. Toxicon. 2013;63:83-87.
    1. Tandon HK, Stratton P, Sinaii N, Shah J, Karp BI. Botulinum toxin for chronic pelvic pain in women with endometriosis: a cohort study of a pain- focused treatment. Reg Anesth Pain Med. 2019;44:886-892.
    1. Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol. 2004;44:46-50.
    1. Bertolasi L, Frasson E, Cappelletti JY, Vicentini S, Bordignon M, Graziottin A. Botulinum neurotoxin type a injections for vaginismus secondary to vulvar vestibulitis syndrome. Obstet Gynecol. 2009;114:1008-1016.
    1. Diomande I, Gabriel N, Kashiwagi M, Piero G, Joellen G, Daniel W. Subcutaneous botulinum toxin type A injections for provoked vestibulodynia: a randomized placebo-controlled trial and exploratory subanalysis. Arch Gynecol Obstet. 2019;299:993-1000.
    1. Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum toxin type A Improvement in pelvic pain with botulinum toxin type A--Single vs. repeat injections. A novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med. 2009;6:2523-2537.
    1. Hansen TH, Guldberg R, Meinert M. Botulinum toxin-treatment of localized provoked vulvodynia refractory to conventional treatment. Eur J Obstet Gynecol. 2019;234:6-9.
    1. Pelletier F, Girardin M, Humbert P, Puyraveau M, Aubin F, Parratte B. Long-term assessment of effectiveness and quality of life of OnabotulinumtoxinA injections in provoked vestibulodynia. J Eur Acad Dermatol Venereol. 2016;30:106-111.
    1. Francisco GE. Botulinum toxin: dosing and dilution. Am J Phys Med Rehabil. 2004;83:S30-S37.
    1. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int. 2005;25:604-611.
    1. Wang J, Yu J, Yu T, et al. Lidocaine injection in the intramuscular innervation zone can effectively treat chronic neck pain caused by MTrPS in the trapezius muscle. Pain Physician. 2015;18:E815-E826.
    1. Cummings TM, White AR. Needling therapies in the management of myofascial trigger point pain: a systematic review. Arch Phys Med Rehabil. 2001;82:986-992.
    1. Takeshige C, Sato M. Comparisons of pain relief mechanisms between needling to the muscle, static magnetic field, external qigong and needling to the acupuncture point. Acupunct Electrother Res. 1996;21:119-131.
    1. George A, VanEtten L, Briggs M. Dry needling for female chronic pelvic pain. J Womens Health Phys Therap. 2018;42:8-16.
    1. Locke L, Neumann P, Thompson J, Briffa K. Management of pelvic floor muscle pain with pelvic floor physiotherapy incorporating neuroscience-based pain education: a prospective case-series report. ANZCJ. 2019;25:30-39.
    1. Berghmans B. Physiotherapy for pelvic pain and female sexual dysfunction: an untapped resource. Int Urogynecol J. 2018;29:631-638.
    1. Lannin NA, Ada L, English C, Ratcliffe J, Crotty M. Effect of adding upper limb rehabilitation to botulinum toxin-A on upper limb activity after stroke: Protocol for the InTENSE trial. Int J Stroke. 2018;13:648-653.
    1. Bonnyaud C, Gallien P, Decavel P, et al. Effects of a 6-month self-rehabilitation programme in addition to botulinum toxin injections and conventional physiotherapy on limitations of patients with spastic hemiparesis following stroke (ADJU-TOX): Protocol study for a randomised controlled, invest. BMJ Open. 2018;8:e020915.
    1. Hirsch M, Duffy JMN, Kusznir JO, Davis CJ, Plana MN, Khan KS. Variation in outcome reporting in endometriosis trials: a systematic review. Am J Obstet Gynecol. 2016;214:452-464.
    1. Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005;14:798-804.
    1. Frahm Olsen M, Bjerre E, Hansen MD, Tendal B, Hilden J, Hróbjartsson A. Minimum clinically important differences in chronic pain vary considerably by baseline pain and methodological factors: systematic review of empirical studies. J Clin Epidemiol. 2018;101:87-106.e2.
    1. Meister MR, Shivakumar N, Sutcliffe S. Physical examination techniques for the assessment of pelvic floor myofascial pain: a systematic review. Am J Obstet Gynecol. 2018;219:497.e1-497.e13.
    1. Meister MR, Sutcliffe S, Ghetti C, et al. Development of a standardized, reproducible screening examination for assessment of pelvic floor myofascial pain. Am J Obstet Gynecol. 2019;220:255.e1-255.e9.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel